The Cannabis Conversation Podcast
The Cannabis Conversation is the leading English-speaking podcast exploring the legal cannabis industry from a European perspective.
Founded in 2019 by commercial lawyer Anuj Desai, the show has spent six years bringing together the people shaping this industry - operators, scientists, investors, clinicians, policymakers, and entrepreneurs, for honest, evidence-based conversations that go beyond the headlines.
With 194 episodes, The Cannabis Conversation has become a trusted resource for professionals navigating one of the world's fastest-moving sectors.
In late 2025, Anuj passed the reins to Nikita Cretu & Thomas Gray from Lumino - Europe's leading cannabis recruitment agency, who have taken stewardship of the podcast's next chapter. Powered by the belief that an industry is only as good as the people in it, the show continues its mission: to illuminate the industry by bringing the right voices into the seat.
Guests span the full spectrum, from founders and operators deep inside the cannabis world to leaders from other highley regulated markets like pharma, Tobacco, Alcohol, and beyond who are paying close attention.
The Cannabis Conversation Podcast
EPISODE #120 Cannabinoid Hyperemesis Syndrome with Dr. Ethan Russo, Founder of Credo Science
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
What is Cannabinoid Hyperemesis Syndrome (CHS)?
This week, we welcome back Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis.
In this episode, Dr Russo shares the latest research and findings of the largest study on CHS to date - in which his team identified 6 potential genetic targets to assist in the diagnosis and treatment of the condition.
→ View full show notes, summary, and access resources here:
https://www.canverse.global/shownotes/e120
About Dr. Ethan Russo
Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com
Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.
He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.
Resources
Join Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/
View Dr. Russo’s clinical research papers: https://www.researchgate.net/profile/Ethan_Russo
CReDO Science Website: https://credo-science.com/
Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Paper: https://pubmed.ncbi.nlm.nih.gov/34227878/
❇️ Get in touch at https://www.thecannabisconversation.co.uk
Connect with Nikita Cretu on LinkedIn:
https://www.linkedin.com/in/nikita-cretu-b24b83a8/
Connect with Thomas Gray on LinkedIn:
https://www.linkedin.com/in/thomas-c-s-gray/
🔋 The Cannabis Conversation is powered by Lumino - Europe's leading HR and Recruitment Agency specialising in building high performance teams for the legal cannabis industry. They work in three main verticals: Commercial, Medical and Plant-Facing. From HR advisory and executive search services to hiring support for full-time placements, consultants, or contract staff, Lumino has helped hundreds of companies of all sizes in the industry scale sustainably through the right people.
🌱 Need support finding the right talent to GROW your business? Book a call with our recruitment team at: https://calendly.com/d/zvg-y2d-tgc